Antibody Drugs: Technologies and Global Markets

Report Code: BIO016J

Publish Date: Jan 2015

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for antibody drugs was worth nearly $63.4 billion in 2013. This market is expected to grow at a compound annual growth rate (CAGR) of 12.2% between 2014 and 2019 resulting in totals nearly $68.9 billion in 2014 and $122.6 billion globally in 2019.

Report Includes

  • An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
  • Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
  • Analysis and assessment of the therapeutic applications of mAbs in human medicine.
  • A look at the antibody industry as a whole as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
  • Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

Report Scope

The scope of this report embraces the key market analysis, market drivers, market constraints, and also competitive developments and trends in this market. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections and market shares.

The study involves the antibody drugs used in the pharmaceutical and the biopharmaceutical markets. This report analyzes and assesses therapeutic applications of mAbs in human medicine, including the combination of mAbs when they are attached to cytotoxic agent such as with antibody-drug conjugates (ADCs).

Excluded from this report is information regarding polyclonal antibodies, as well as screening equipment and diagnostic uses (such as for imaging purposes) of mAbs. Also excluded is discussion relating to the research applications of mAbs and therapeutic antibodies for veterinary use.

Complete geographical analysis of market is also studied in report. The emerging market for mAbs includes countries such as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth. Profiles of key market players are also covered for this report. The U.S. and Europe markets are also covered.

The technological issues include all the latest trends, for example, the human antimouse antibody (HAMA) problem because of murine antibodies and its resolution by using chimeric, human and humanized antibodies instead of murine antibodies for therapy, pipeline products and developments. Also included in the report are comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development (R&D) of antibody drugs.

Need pricing for multiple titles, a complete report bundle, or something specially curated to fit your budget? EXPLORE OFFERS

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Antibody Drugs: Technologies and Global Markets141Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY2Free
Chapter- 3: OVERVIEW15Free
Chapter- 4: REGULATORY ASPECTS8Free
Chapter- 5: NEW DEVELOPMENTS15Free
Chapter- 6: MARKET ANALYSIS OF ANTIBODY DRUGS30Free
Chapter- 7: MARKET APPLICATIONS OF ANTIBODY DRUGS28Free
Chapter- 8: INDUSTRY STRUCTURE8Free
Chapter- 9: PATENT ANALYSIS9Free
Chapter- 10: CURRENT SITUATION 9Free
Chapter- 11: C. CRAMER & CO. GMBH11Free
Chapter- 12: APPENDIX ABBREVIATIONS2Free

Related Reports

Global Markets for Telemedicine Technologies

Published - Sep 2014 | Publisher - Andrew McWilliams | Code - HLC014G

The global telehospital/clinic and telehome market reached $16.3 billion in 2013 and $19.2 billion in 2014, and should reach about $43.4 billion in 2019 with a compound annual growth (CAGR) of 17.7% through 2019.

Pulmonary Drug Delivery Systems: Technologies and Global Markets

Published - May 2014 | Publisher - Usha Nagavarapu | Code - HLC094B

The global market for pulmonary drug delivery technologies reached $32.4 billion in 2013 and is expected to grow to $43.9 billion in 2018, with a compound annual growth rate (CAGR) of 6.2%.

Anesthesia and Respiratory Devices: Global Markets

Published - Feb 2014 | Publisher - Vijay Laxmi | Code - HLC167A

The global market for anesthetic and respiratory devices reached $11.1 billion in 2012. This market is expected to grow to $12.4 billion in 2013 and $19.6 billion in 2018 with a compound annual growth rate (CAGR) of 9.5% for the five-year period, 2013 to 2018.

DNA Sequencing: Emerging Technologies and Applications

Published - Feb 2014 | Publisher - John Bergin | Code - BIO045E

The global market for sequencing products and services reached $3.5 billion in 2012. This market is expected to grow to nearly $4.5 billion in 2013 and nearly 11.7 billion in 2018, a compound annual growth rate (CAGR) of 21.2%.

Track the Latest Global Tariff Developments

In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.

Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.

Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.

With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.

Ready to see what tariff means for your business?

Consult with our experts or request your custom Tariff Impact Brife today

Stay Informed, Stay Competitive

In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.

Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.

Our analysis includes:

  • Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
  • Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
  • Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.

With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.

Don't let tariffs catch you off guard—let our insights guide your strategy.

This is an Excel-only version of the report.

Report Includes

    Total Number of Tables in this Report: 66

  • Summary Table: GLOBAL MARKET FOR ANTIBODY DRUGS BY REGION, THROUGH 2019
  • Table 1: EVOLUTION OF MONOCLONAL ANTIBODIES
  • Table 2: ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
  • Table 3: DIFFERENCES BETWEEN MONOCLONAL ANTIBODY DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
  • Table 4: MURINE MONOCLONAL ANTIBODIES
  • Table 5: CHIMERIC MONOCLONAL ANTIBODIES
  • Table 6: HUMANIZED MONOCLONAL ANTIBODIES
  • Table 7: HUMAN MONOCLONAL ANTIBODIES
  • Table 8: DIFFERENCES BETWEEN HYBRIDOMA TECHNOLOGY AND RECOMBINANT TECHNOLOGY
  • Table 9: COMPARISON OF VARIOUS EXPRESSION SYSTEMS FOR RECOMBINANT PHARMACEUTICAL PROTEINS
  • Table 10: MURINE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS
Sample Report

Recent Reports

Global Biochip Markets: Microarrays and Lab-on-a-Chip

Published - Jun 2025 | Publisher - BCC Publishing | Code - BIO049G

The global market for biochip was valued at $16.1 billion in 2024 and is estimated to reach $27.8 billion by 2029, at a compound annual growth rate (CAGR) of 11.6% from 2024 through 2029.

Global Cell Line and Membrane Market

Published - Jun 2025 | Publisher - BCC Publishing | Code - BIO178B

The global market for cell lines and membranes was valued at $5.7 billion in 2024 and is estimated to increase from $6.3 billion in 2025 to reach $11.4 billion by 2030, at a compound annual growth rate (CAGR) of 12.5% from 2025 through 2030.

Human Microbiome-based Drugs and Diagnostics: Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - BIO151B

The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.

Global Microbiome Sequencing Market

Published - May 2025 | Publisher - BCC Publishing | Code - BIO183B

The global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029.

Proteomics: Technologies and Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - BIO034G

The global market for proteomic technologies was valued at $27.6 billion in 2024. It is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030.

Top Trending Reports

Global Markets and Manufacturing Technologies for Protein Drugs

Published - Apr 2025 | Publisher - BCC Publishing | Code - BIO021G

The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

Next-Generation Advanced Batteries: Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - FCB062B

The global market for next-generation advanced batteries is estimated to grow from $1.5 billion in 2024 to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 28.5% from 2024 through 2029.

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

Published - May 2025 | Publisher - BCC Publishing | Code - PHM263B

This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

Biologic Therapeutic Drugs: Technologies and Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - BIO079F

The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.

2024 Medical Devices Research Review

Published - Mar 2025 | Publisher - BCC Publishing | Code - MDS060B

The medical device industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years These devices treat and diagnose a multitude of patient conditions and work much better than drugs.

Published - Feb-2012| Analyst - Esther Bosklopper| Code - BIO016H

Report Highlights

The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011.  With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.

Published - Jan-2008| Analyst - Kim Lawson| Code - BIO016G

Report Highlights

This Report:

  • The global market for monoclonal therapeutic and diagnostic antibodies increased from $26 billion in 2006 to an estimated $31 billion by the end of 2007. It should reach $56 billion by 2012, a compound annual growth rate (CAGR) of 13%.
  • In 2007, the U.S. Food and Drug Administration approved 21 therapeutic monoclonal antibodies for therapeutic use under a drug approval review.
  • Monoclonal antibodies are a significant part of effective medical treatment and of financial deals within the biotechnology and pharmaceutical sectors of the economy.
Published - Aug-2005| Analyst - Lynn Gray| Code - BIO016F

Report Highlights

  • The worldwide market for therapeutic and diagnostic antibodies is estimated at $15 billion in 2005 and will rise at an average annual growth rate (AAGR) of 11.5% to nearly 26 billion in 2010.
  • Therapeutic antibodies dominate the market and are projected to have an AAGR of 11.4%, reaching $25.7 billion in 2010.
  • The therapeutic monoclonal antibody segment will rise at an AAGR of 12.4% while the therapeutic polyclonal market, driven more by volume and demand than innovation, is projected to see an AAGR of only 4%.
  • The diagnostic imaging market, though small, will experience an average annual growth near 17%, reaching $147 million in 2010.
Published - Oct-2002| Analyst - Lynn Gray| Code - BIO016E

Report Highlights

  • As of May 2002, there were 11 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 470 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 70 of these monoclonal antibody products were in clinical trials. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), monoclonal antibody products represented approximately 20% of all products in development and 33% of all biotech products in development by its members.
  • The therapeutic monoclonal antibody market is projected to have an average annual growth rate (AAGR) of approximately 25% throughout the forecast period. The therapeutic polyclonal antibody market, which is driven more by volume and demand than innovation, is projected to see an AAGR of just less than 11%. The diagnostic imaging market, though small, will see average annual growth exceeding 28% throughout the forecast period.

Published - Feb-2000| Analyst - Lynn Gray| Code - BIO016D

Report Highlights

  • Antibody-based drugs, in particular monoclonal antibody-based products, are on the brink of significant commercial growth. New developments are spurred in part by advances in technology that have now surmounted previous technical barriers to commercialization.
  • The information and analyses presented in this report on antibody-based drugs is an important asset in decision-making for managers involved in development, marketing, market research, product development, mergers and acquisitions, licensing, management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry.
  • The study provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Antibody Drugs: Technologies and Global Markets
Customize Report